Clinical trial Recruiting at 1 site Interventional Ages 60 to 75

Synbiotic blend of LA-5 and agave inulin for mild cognitive impairment

Official title: Effect of a Symbiotic (Lactobacillus Acidophilus LA-5 and Agave Inulin) on Mild Cognitive Impairment in Older Adults of the Defense Medical Specialties Unit

Run by Anahuac University · NCT07818369 · Data updated 2026-11-12

This pilot crossover study tests whether a synbiotic containing Lactobacillus acidophilus LA-5 and agave inulin can help adults aged 60–75 with mild cognitive impairment.

More Cognitive Impairment trials

Quick facts

Study typeInterventional
Ages60 Years to 75 Years
SexAll
Enrollment20 (estimated)
SponsorAnahuac University
Academic / other
Locations1 site (Mexico City, Mexico City)
StatusRecruiting
StartedDecember 31, 2026
Main results expectedNovember 1, 2027
Study endsNovember 30, 2027
Registry record updatedSeptember 14, 2026
Trial IDNCT07818369 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 60–75 with mild cognitive impairment confirmed by neuropsychological testing (MoCA 19–26, M@T 28–37, MMSE 12–24) who can provide informed consent.

Probably not a fit

Individuals without MCI per testing or those with certain competing diagnoses may not experience a cognitive benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a small, randomized, double-blind crossover trial in adults with mild cognitive impairment. Participants will receive a synbiotic containing Lactobacillus acidophilus LA-5 and agave inulin for 12 weeks, then switch to a control in almond powder after a 2-week washout, for another 12 weeks. Cognitive function will be measured with MoCA, M@T, and MMSE, while exploratory biomarkers related to the microbiota-gut-brain axis will be assessed in stool and blood. The study aims to explore whether the synbiotic can influence cognitive outcomes and gut-derived biomarkers in this population.

Why it matters

Potential benefit: If successful, participants may experience improvements in cognitive test performance and gains in understanding of gut-brain interactions related to MCI.

How similar studies have gone: Similar synbiotic approaches have shown signals of gut-brain biomarker changes in cognitive populations, but definitive cognitive benefits remain exploratory, making this study relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults aged 60 to 75 years.
* Presence of mild cognitive impairment (MCI) determined by neuropsychological testing, meeting at least two of the following three established cutoff criteria:
* Montreal Cognitive Assessment (MoCA): 19-26 points.
* Memory Alteration Test (M@T): 28-37 points.
* Mini-Mental State Examination (MMSE): 12-24 points.
* Ability and willingness to provide written informed consent; consent may be provided by a family member or legal representative when necessary.

Exclusion Criteria:

* Previous diagnosis of severe cognitive impairment, Alzheimer disease, vascular dementia, or another neurodegenerative disorder affecting cognition.
* History of cerebral ischemia, cerebrovascular events, traumatic brain injury, or advanced-stage renal disease.
* Diagnosis of type 2 diabetes mellitus.
* Diagnosed dysbiosis or inflammatory bowel disease, including ulcerative colitis or Crohn disease.
* Use of antibiotics, laxatives, probiotics, or prebiotics within the 3 months prior to enrollment.
* Habitual consumption of fermented foods or fiber-rich supplements, particularly fiber intake \>18 g/day.
* Excessive alcohol consumption, defined as ≥2 alcoholic drinks per day, or history of alcohol dependence.
* Chronic use of medications that may interfere with the microbiota-gut-brain axis, including immunosuppressants, antipsychotics, or corticosteroids.
* Recent surgery within the previous 3 months or a planned medical intervention during the study period.
* Known adverse reaction or hypersensitivity to any component of the synbiotic or to almond powder.
* Uncontrolled chronic stress identified by clinical assessment.
* Participation in intense physical activity or high-performance sports during the study.

Where it's running

  • Unidad de Especialidades Médicas de la Defensa (UEMD)
    Mexico City, Mexico City, Mexico
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.